A Phase 3 Multi-center, Open-Label Study to Evaluate Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents With Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to Biologic or Non Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs)
Latest Information Update: 12 Jul 2024
At a glance
- Drugs Abatacept (Primary)
- Indications Juvenile rheumatoid arthritis
- Focus Pharmacokinetics; Registrational
- Acronyms JIA-2
- Sponsors Bristol-Myers Squibb
- 25 Jun 2024 Results investigating the propensity of S100A8/9 and S100A12 as predictive biomarkers of abatacept response in polyarticular-course juvenile idiopathic arthritis , published in the Arthritis Research and Therapy
- 14 Jun 2023 Status changed from active, no longer recruiting to completed.
- 23 Sep 2022 Last checked against the ClinicalTrials.gov record.